Viridian Therapeutics
Enters commercial stage with Lumvoa, an intravenous IGF-1R antibody for thyroid eye disease.
$23.08
After-hours close−0.01 (−0.04%)
At close$23.09(−3.31%)
Something off on this page? Send us feedback.
Breakdown13F · Form 4
Institutions 122.21%Insiders 4.59%
A 13F quarter can total more than the shares outstanding — sub-advisers file the same block twice, and a filer's own share count can be a quarter stale. No split is drawn from it.
Shares outstanding 113.29M · Float 105.16M · 92.8% free float
Institutions13F, as of Jun 30, 2026
226 holders · 138.45M shares · 50 new positions · 143 increased · 54 reduced · 55 closed
| Holder | Shares | % outstanding | Chg q/q | Filed |
|---|---|---|---|---|
| FMR LLC | 16.60M | 14.66% | +1.23M | Aug 13, 2026 |
| BlackRock, Inc. | 8.55M | 7.55% | +720.0K | Aug 7, 2026 |
| Bellevue Group AG | 6.73M | 5.94% | +5.8K | Aug 14, 2026 |
| Paradigm Biocapital Advisors LP | 6.72M | 5.93% | +3.57M | Aug 14, 2026 |
| Kynam Capital Management, LP | 6.45M | 5.70% | +4.11M | Aug 14, 2026 |
| State Street Corp | 6.12M | 5.41% | +1.45M | Aug 7, 2026 |
| Price T Rowe Associates Inc /MD/ | 5.75M | 5.07% | +2.54M | Aug 14, 2026 |
| Fairmount Funds Management LLC | 5.09M | 4.49% | +1.18M | Aug 14, 2026 |
Beneficial owners13D/G · 5% or more, as filed
| Holder | % of class | Shares | Form | Filed |
|---|---|---|---|---|
| Fairmount Healthcare Fund II GP LLCincl. Fairmount Funds Management LLC | 14.04% | 17.20M | 13D | May 13, 2026 ↗ |
| Bellevue Group AG | 6.60% | 6.73M | 13G | May 15, 2026 ↗ |
| State Street Corporation | 5.50% | 6.12M | 13G | Aug 7, 2026 ↗ |
| Deep Track Capital, LP | 5.30% | 5.42M | 13G | May 8, 2026 ↗ |
| Commodore Capital LP | 5.30% | 4.30M | 13G | Apr 11, 2025 ↗ |
| T. Rowe Price Associates, Inc. | 5.20% | 5.75M | 13G | Aug 14, 2026 ↗ |
| Paradigm BioCapital Advisors LP | 5.10% | 5.63M | 13G | Jun 26, 2026 ↗ |
| Point72 Asset Management, L.P. | 5.00% | 5.69M | 13G | Aug 20, 2026 ↗ |
InsidersForm 4
| Insider | Role | Shares | % outstanding | Filed |
|---|---|---|---|---|
| Fairmount Funds Management LLC | director, 10 percent owner: | 5.09M | 4.49% | May 13, 2026 |
| Radhika Tripuraneni | officer: Chief Medical Officer | 40.0K | 0.04% | Aug 18, 2026 |
| Stephen F. Mahoney | director, officer: President and CEO | 33.3K | 0.03% | Mar 9, 2026 |
| Thomas W. Beetham | officer: Chief Operating Officer | 13.4K | 0.01% | Mar 9, 2026 |
| Jennifer Tousignant | officer: Chief Legal Officer | 10.0K | 0.01% | Aug 20, 2026 |
| Seth Harmon | officer: Chief Financial Officer | 7.9K | 0.01% | Mar 9, 2026 |
6 ten-percent owners hold 3.28M shares by Form 4, outside the officers-and-directors figure above · 18 people have not refiled in the last 18 months (2.48M shares), so they are not in the figure above
Latest trades
| Date | Insider | Type | Shares | Avg price | Owned after |
|---|---|---|---|---|---|
| Aug 19, 2026 | Jennifer Tousignantofficer: Chief Legal Officer | Sale | 10,000 | $24.50 | 0 |
| May 11, 2026 | Fairmount Funds Management LLCdirector, 10 percent owner: | Purchase | 1,176,470 | $17.00 | 5,090,928 |
| Dec 31, 2025 | Jennifer Tousignantofficer: Chief Legal Officer | Sale | 2,272 | $31.16 | 0 |
| Oct 23, 2025 | Fairmount Funds Management LLCdirector, 10 percent owner: | Purchase | 454,545 | $22.00 | 3,914,458 |
CongressHouse and Senate disclosures
Not reported.